EMUC15: Prostate cancer studies win best unmoderated poster awards

14 November 2015 Joel Vega

Three studies in prostate cancer treatment have won the best unmoderated posters at the second day of the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC15). Researchers in the Netherlands, Italy and a multi-centre study involving institutions in France and Italy were cited for their insights in prostate cancer therapies. Six best oral abstracts were also presented covering topics such as bladder cancer, localized and advance prostate cancers.

Below are the list of winners for the best unmoderated posters and the six best oral presentations:

Best Unmoderated Poster Presentations:

  • Oderda M. et al., “Natural history of prostate widespread HGPIN and ASAP: When to rebiopsy?”
  • Venderbos, L. D. F. et al., “Quality of life of men on active surveillance for prostate cancer versus men without prostate cancer: Are there any differences?”
  • Cozzarini, C. et al., “Toxicity and efficacy of salvage tomotherapy Choline PET/CT guided in patients with prostate cancer lymph nodal recurrence”

Six Best Oral Presentations:

  • Bellmunt J. et al., “First-line randomized phase 2 study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The international Borealis-1™ trial”
  • Dearnaley D. et al., “Phase 2 study of investigational oral GnRH antagonist TAK-385 (relugolix) in patients with intermediate risk localized prostate cancer requiring neoadjuvant and adjuvant androgen deprivation therapy (ADT) with external beam radiation therapy (EBRT): Results from the 12-week interim analysis”
  • Cozzarini C. et al., “Clinico-dosimetric factors predicting long-term severe urinary incontinence after post-prostatectomy RT. Results of a longitudinal observational study”
  • Bokhorst L.P., et al., “Should we start screening men for prostate cancer before the age of 55?”
  • Carles J. et al., “Effect of baseline characteristics on overall survival in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)”
  • Lara P. et al., “SWOG 0421: Impact of circulating markers of bone metabolism on overall survival in men with metastatic Castration Resistant Prostate Cancer (CRPC)”